Close Menu

The Next Biotech

IMC Hits Key Milestones Ahead of Imminent NASDAQ Listing

Immuron Limited (ASX: IMC) is working in the realm of oral immunotherapies, targeting inflammatory-mediated and infectious diseases and is uniquely positioned to address large unmet needs. The global immunotherapy drugs market is projected to reach US$201.52 billion by 2021 from US$108.41 billion in 2016, yet the biggest need could come in the non-alcoholic fatty liver […]

May 17, 2017

CPH Deliver Australia’s First Medicinal Cannabis Shipment Under New Legislation

Creso Pharma (ASX: CPH) has made a shipment of medicinal cannabis into Australia – the first import into the country under new government legislation. Under an agreement between CPH and its Australian partner, Health House International Pty Ltd, the pair will distribute a range of cannabis oil products across Australian pharmacies, in compliance with Federal and State legislation.

May 2, 2017

ASX Stock to Launch on NASDAQ with Gut Busting Immunotherapy Products

Today’s $30 million capped ASX listed biotech player, which is in the process of listing on the NASDAQ, has thus far flown right under the radar of Australia’s biotech landscape. This scenario is likely to change, however, as this cutting edge company has chosen to take aim at the oral immunotherapy sector, with antibody products […]

Mar 24, 2017

Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big Pharma Deal?

One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease. To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures. One $30 million capped ASX junior may have a unique solution.

Mar 16, 2017

Current Stocks